Drug Trial Radar · NCT00232687
A Switch Study of BMS-337039 in Schizophrenic Out-patients
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Jun 1, 2005
Primary completion
Apr 1, 2007
Study completion Apr 1, 2007
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- Otsuka America Pharmaceutical
- First posted
- Oct 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.
Conditions
- Schizophrenia
Interventions
AripiprazoleDrug
Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
AripiprazoleDrug
Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients who discontinue because of Adverse EventsTime frame: Up to 22 months
Locations
72 sites in 10 countries. Site status is shown where the registry gives one.
Local Institution
Hall in Tirol, Austria
Local Institution
Vienna, Austria
Local Institution
Bruges, Belgium
Local Institution
Brussels, Belgium
Local Institution
Diest, Belgium
Local Institution
Halle, Belgium
Local Institution
Sint-Denijs-Westrem, Belgium
Local Institution
Stokrooie, Belgium
Local Institution
Havířov, Czechia
Local Institution
Olomouc, Czechia
Local Institution
Prague, Czechia
Local Institution
Přerov, Czechia
Local Institution
Aubagne, France
Local Institution
Bordeaux, France
Local Institution
Brumath, France
Local Institution
Château-Gontier, France
Local Institution
Clermont-Ferrand, France
Local Institution
Dijon, France
Local Institution
Dommartin-lès-Toul, France
Local Institution
Fains-Véel, France
Local Institution
Hénin-Beaumont, France
Local Institution
Le Pecq, France
Local Institution
Lyon, France
Local Institution
Poitiers, France
Local Institution
Reims, France
Local Institution
Roubaix, France
Local Institution
Toulon, France
Local Institution
Toulouse, France
Local Institution
Achim, Germany
Local Institution
Bochum, Germany
Local Institution
Cologne, Germany
Local Institution
Ellwangen, Germany
Local Institution
Hattingen, Germany
Local Institution
Nuremberg, Germany
Local Institution
Osnabrück, Germany
Local Institution
Ostfildern, Germany
Local Institution
Witten, Germany
Local Institution
Athens, Greece
Local Institution
Chania, Greece
Local Institution
Corfu, Greece
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.